NASDAQSCLX

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada - Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada – Scilex Holding (NASDAQ:SCLX)

Scilex Holding Announces Issuance Of Halal Certification For Its ZTlido® Product By Circle H International, Inc. - Scilex Holding (NASDAQ:SCLX)

Scilex Holding Announces Issuance Of Halal Certification For Its ZTlido® Product By Circle H International, Inc. – Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered Into A Definitive Mutual Release And Settlement Agreement With Virpax Pharmaceuticals, Inc. Relating To The Previously Announced Term Sheet With Virpax In Respect Of Such Release And Settlement - Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered Into A Definitive Mutual Release And Settlement Agreement With Virpax Pharmaceuticals, Inc. Relating To The Previously Announced Term Sheet With Virpax In Respect Of Such Release And Settlement – Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company Sets Launch Price Of $595 Per 150ml Bottle Of Gloperba®, Its First And Only Liquid Oral Version Of The Anti-Gout Medicine Colchicine Indicated For The Prophylaxis Of Painful Gout Flares In Adults; Expected Plans To Launch In The First Half Of 2024 - Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company Sets Launch Price Of $595 Per 150ml Bottle Of Gloperba®, Its First And Only Liquid Oral Version Of The Anti-Gout Medicine Colchicine Indicated For The Prophylaxis Of Painful Gout Flares In Adults; Expected Plans To Launch In The First Half Of 2024 – Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company Announces $10 Million Bought Deal Offering - Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company Announces $10 Million Bought Deal Offering – Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company Announces Major Initiative With A Leading National Pharmacy Chain To Stock GLOPERBA® In Most Of Their Stores Throughout the U.S. - Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company Announces Major Initiative With A Leading National Pharmacy Chain To Stock GLOPERBA® In Most Of Their Stores Throughout the U.S. – Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters Into A Term Sheet With Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement - Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters Into A Term Sheet With Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement – Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company Announces Acceptance Of Abstract For Poster And Oral Presentation At The Annual Meeting Of The American Academy Of Pain Medicine (AAPM) - Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company Announces Acceptance Of Abstract For Poster And Oral Presentation At The Annual Meeting Of The American Academy Of Pain Medicine (AAPM) – Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company Announces That ZTlido® Achieves A Major Milestone - Over One Million Patients Treated Since Its Launch - And Two Additional Milestones Met - Scilex Holding (NASDAQ:SCLX)

Scilex Holding Company Announces That ZTlido® Achieves A Major Milestone – Over One Million Patients Treated Since Its Launch – And Two Additional Milestones Met – Scilex Holding (NASDAQ:SCLX)

top